Cell Therapeutics Pre-Meeting Bounce (CTIC)

Posted in pre-market 
April 9th, 2010

Cell Therapeutics, Inc. (NASDAQ: CTIC) is up ahead of its special shareholder meeting; and after it announced that the company has received a FDA complete response letter over its new drug application for pixantrone for relapsed or refractory aggressive non-Hodgkin’s lymphoma.  It is going to keep marching forward with current and new indications.  Shares are trading up over 3% at $0.657 on 1.3 million shares as of 8:34 AM EST.


Comments are closed